Catalent Biologics Adds New Technology Platform
News Jul 09, 2015
Catalent, Inc. has announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture.
Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also be able to leverage its own proprietary GPEx® technology to help enable that development.
“Combination antibody therapies are becoming the treatment standard for many indications within oncology, immuno-oncology, and infectious diseases,” commented Mike Riley, Vice President/General Manager, Catalent Biologics.
He added, “This technology platform has the potential to allow production of multiple antibodies in a significantly more cost-effective manner. This can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients.”
Excelimmune's antibody combination expression system is based on a key innovation: the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies.
This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic.
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE